Coronary Artery Calcium-guided Primary Prevention of Major Coronary Heart Disease in Asymptomatic Diabetes
Launched by JUFENG, HSIAO · Mar 1, 2022
Trial Information
Current as of August 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Background The patients with type two diabetes mellites increased gradually and heart disease and cerebral vascular disease is the fourth leading cause of mortality. According to the National Health Insurance Research Database (NHIRD) till 2014, incidence of coronary heart disease is 25.2% and heart failure is 3.77%。Multiple complication including chronic kidney disease and cerebrovascular diseases were also well-known.
A systematic review study of scientific evidence from across the world in 2007-2017 revealed cardiovascular disease (CVD) affected 32.2% overall; 29.1% had atherosclerosis,...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • more than 40 years old T2DM patients have any one cardiovascular risk as follows
- • 1. total cholesterol\>200mg/dl or low density lipoprotein (LDL) \>100mg/dl
- • 2. blood pressure\>140/90mm/Hg or taking anti-hypertension agents
- • 3. history of smoking
- • 4. family history of early coronary heart diseases
- • 5. proteinuria
- Exclusion Criteria:
- • history of cardiovascular diseases such as coronary heart disease, stroke, heart failure etc, pregnant
About Jufeng, Hsiao
Jufeng Hsiao is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing cutting-edge therapies, Jufeng Hsiao collaborates with healthcare professionals and institutions to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. The organization prioritizes patient safety and data integrity, utilizing state-of-the-art methodologies to ensure robust and reliable outcomes. Through its comprehensive approach to trial management, Jufeng Hsiao aims to contribute significantly to the healthcare landscape, facilitating the development of effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yilan, , Taiwan
Patients applied
Trial Officials
Meng-Huan Lei, MD
Principal Investigator
cardiovascular center, Lo-Tung Poh-Ai Hospital, Taiwan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials